NextCure

NXTC

Market cap $14.5M

Overview Fund Activity

5.40 USD

-0.04

0.74%

At close Updated Sep 12, 4:00 PM EDT

1 day

-0.74%

5 days

9.09%

1 month

11.57%

3 months

-30.77%

6 months

-37.5%

Year to date

-45.23%

1 year

-67.39%

5 years

-95.13%

10 years

-97.74%

About: NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Employees: 43

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1.44% less ownership

Funds ownership: 4.57% [Q1] → 3.13% (-1.44%) [Q2]

18% less funds holding

Funds holding: 38 [Q1] → 31 (-7) [Q2]

23% less capital invested

Capital invested by funds: $7.38M [Q1] → $5.65M (-$1.73M) [Q2]

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

70% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 10

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$15

178% upside

Avg. target

$26

372% upside

High target

$36

567% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Piper Sandler Edward Tenthoff	$15	Overweight Maintained	15 Jul 2025
HC Wainwright & Co. Emily Bodnar	$36	Buy Reiterated	1 Jul 2025

See Analyst Rankings

Financial journalist opinion

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the H.C.

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

The Motley Fool

NextCure (NXTC) Q2 Loss Widens 71%

NextCure (NXTC) Q2 Loss Widens 71%

NextCure (NXTC) Q2 Loss Widens 71%

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

BELTSVILLE, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported second quarter 2025 financial results.

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of new preclinical data in a well-established model of osteogenesis imperfecta (OI) demonstrating that treatment with NC605, a novel anti-Siglec-15 antibody, achieved improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment.

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

Drug developer NextCure said on Monday it had signed a deal worth up to $745 million with China-based drugmaker Simcere Zaiming to develop a cancer therapy for solid tumors.

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

BELTSVILLE, Md. and SHANGHAI, June 16, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, and Simcere Zaiming, an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced a strategic partnership to develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. SIM0505 is currently in Phase 1 clinical testing in China; NextCure expects to begin clinical testing in the U.S. in the third quarter of 2025.

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

BELTSVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, together with LigaChem Biosciences, Inc. (LigaChemBio) announced that a trial in progress poster from the Phase 1 study evaluating LNCB74, a B7-H4 targeted antibody-drug conjugate (ADC), will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025 Plan to provide a proof of concept data readout in the first half of 2026 Cash of approximately $55.9 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., May 01, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported first quarter 2025 financial results.

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET.

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

BELTSVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported full year 2024 financial results.

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™